MediaPlatform Introduces ScreenCaster Product
13 avr. 2015 07h30 HE
|
MediaPlatform, Inc.
LAS VEGAS, NV--(Marketwired - Apr 13, 2015) - NAB Show - MediaPlatform, Inc. (www.mediaplatform.com), the leading enterprise video platform enabling on-demand streaming and live rich media...
Canadian HIV vaccine researcher explores ways to engage at-risk youth
23 févr. 2015 12h00 HE
|
International Centre for Infectious Disease
WINNIPEG, Feb. 23, 2015 (GLOBE NEWSWIRE) -- In 2012, researcher Mark Brockman was among five Canadian principal investigators to receive funding through the Canadian HIV Vaccine Research Initiative...
Canadian HIV Researcher Gets Back to Basics
01 déc. 2014 09h45 HE
|
International Centre for Infectious Disease
TORONTO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Basic science is helping to inform new discoveries in HIV vaccine research. A Canadian research team is conducting studies to better understand how the immune...
MediaPlatform Recognized as the Top Cloud Webcasting/Presentation Solution
20 nov. 2014 07h30 HE
|
MediaPlatform, Inc.
LOS ANGELES, CA--(Marketwired - Nov 20, 2014) - MediaPlatform, Inc. (www.mediaplatform.com), the leading enterprise video platform, today announced that its enterprise webcasting product WebCaster...
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
18 nov. 2014 05h44 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated
...
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
17 nov. 2014 08h01 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated
...
Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
22 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
14 juil. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance to develop multiple projects with Bioclones...
Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
08 juil. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced execution of an agreement to seek South African government approval...
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
11 févr. 2014 09h27 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...